Compare TEAM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | ROIV |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 23.2B |
| IPO Year | 2015 | 2021 |
| Metric | TEAM | ROIV |
|---|---|---|
| Price | $83.99 | $34.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $169.18 | $28.94 |
| AVG Volume (30 Days) | 4.2M | ★ 5.8M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,215,304,000.00 | $8,260,000.00 |
| Revenue This Year | $24.65 | N/A |
| Revenue Next Year | $17.67 | $744.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $56.01 | $10.71 |
| 52 Week High | $222.52 | $35.90 |
| Indicator | TEAM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 71.26 |
| Support Level | $76.31 | $26.65 |
| Resistance Level | $84.95 | N/A |
| Average True Range (ATR) | 4.54 | 1.17 |
| MACD | -0.65 | 0.39 |
| Stochastic Oscillator | 48.48 | 82.59 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.